Insulin Lispro Injection, Solution
Pricing Report NDC 0002-7737-01

Current NADAC: $2.40277 per ML · Effective Aug 19, 2026

Current Package Pricing Information

The current wholesale acquisition cost for Insulin Lispro (NDC 0002-7737-01) is $2.40277 per ML. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Aug 19, 2026.

As a a human prescription drug provided by Eli Lilly And Company, this medication is distributed in a 1 VIAL in 1 CARTON / 10 mL in 1 VIAL configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.

NADAC Pricing Summary

NADAC pricing snapshot for this package NDC

Acquisition Cost
$2.40277
Per ML

Effective Date
Aug 19, 2026
Data Status
As of Sep 09, 2026
C/I - Chain or Independent Pharmacy
Package NDC
Description
1 VIAL in 1 CARTON / 10 mL in 1 VIAL
Pricing Methodology Explanation
The NADAC was calculated using information from the most recently completed pharmacy survey.
The NADAC was calculated based on package size.
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Historical Pricing Trends & Acquisition Cost Benchmarks

Since Jul 2020, the NADAC wholesale price for (NDC ) has moved within a range of $2.39535 to $13.20979 per ML. Over this 6 years and 1 month period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.

Price Range
$2.3954 - $13.2098
Market Volatility
451.48% Variance
Latest Trend
0.05%

Recent NADAC Price History

DateUnit PriceUnitSourceMethodRate
Aug 19, 2026 $2.40277 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Jul 22, 2026 $2.40388 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Jun 17, 2026 $2.40396 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
May 20, 2026 $2.40430 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Apr 22, 2026 $2.40441 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Mar 18, 2026 $2.40388 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Feb 18, 2026 $2.40484 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Jan 21, 2026 $2.40482 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Dec 17, 2025 $2.40542 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Nov 19, 2025 $2.40485 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Oct 22, 2025 $2.40424 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Sep 17, 2025 $2.40352 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic

Earlier NADAC Price History

Pricing Methodology Legend

  • Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
  • Code 3: The NADAC based on survey data has been adjusted to reflect changes in published pricing, or as a result of an inquiry to the help desk.
  • Code 4: The NADAC was carried forward from the previous file.
  • Code 5: The NADAC was calculated based on package size.
  • Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Understanding NADAC Pricing Data

The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.


Important Price Distinction:

The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.

NADAC Pricing Data Last Updated on: September 09, 2026